BioAtla, Inc. (BCAB)
BCAB is quoted over the counter, not listed on an exchange. BioAtla, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | BCAB, quoted over the counter |
| SEC CIK | 0001826892 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | San Diego, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management's assessment concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the issuance date of these condensed consolidated financial statements." | 10-Q 2026-08-13 |
| Cash and burn | $1.5M cash; operating cash flow -$5.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,666,100 (2026-07-31); 58,721,588 a year earlier. 1y figure adjusted for split (1-for-50 overall). | Cover page 2026-07-31 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-04-06 | Source 2026-04-06 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-11-21 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-08-28 |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-10-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | $452K | -$419K | $1.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$6.3M | -$5.3M | $2.0M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$9.8M | -$7.9M | $7.1M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$15.8M | -$9.9M | $8.3M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$18.7M | -$14.1M | $18.2M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$15.3M | -$16.3M | $32.4M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$14.9M | -$16.8M | $49.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$10.6M | -$5.1M | $56.5M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-29 |
| Latest annual report | 10-K/A | 2026-04-29 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-10-20 |
| Latest proxy | DEFA14A | 2026-06-03 |
Source: SEC EDGAR submissions feed, 510 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier